EIB hands ophthalmology maker Théa €150M R&D loan
What's the deal? The European Investment Bank is lending €150 million to ThéaDealroom has a profile for this one. Try Dealroom →, the Clermont-Ferrand-based ophthalmology company, to fund research and development and expand its European manufacturing. It is the EIB's second loan to Théa, following an initial €50 million financing signed in 2021.
What's the endgame? Founded in 1994, Théa bills itself as Europe's leading independent ophthalmology company and reinvests more than 12% of turnover in research each year. The loan targets strategic programmes in retinal diseases, rare inherited eye diseases, glaucoma, and dry eye.
Why now? The deal backs both new molecules and formulations and the build-out of industrial capacity, including Théa's Milan site. It is expected to benefit from the InvestEU guarantee, backed by the European CommissionDealroom has a profile for this one. Try Dealroom →.
What they're saying: "This new €150 million loan opens a new chapter in our partnership with Théa," said EIB vice-president Ambroise Fayolle. Group president Jean-Frédéric Chibret called the financing "an important milestone and a strong vote of confidence in our long-term strategy."
By the numbers: The EIB Group signed €100 billion in new financing and advisory services across more than 870 projects in 2025.
The signal: The financing points to deepening public-sector support for European biotech, framed around sovereignty in a sector the EIB calls strategic. For Théa, debt rather than equity keeps the independent company in family control while it chases treatments for unmet medical needs.
Read more: eib.org
Image credit: Generated with Gemini